Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RaRE-TS rapamycin trial in drug-resistant epilepsy associated with tuberous sclerosis complex
2021-004548-64Phase 3Active
- Sponsor
- Children's Memorial Health Institute
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epilepsy and tuberous sclerosis complex (TSC) comparing Rapamycin with Placebo (2 arms). Primary endpoint: Responder rate by seizure reduction. Started Dec 2022; status: active.
02
Drugs
sirolimus
03
Conditions
epilepsytuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on 2021-004548-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004548-64.